Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration

The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential uses in breast cancer, but an unacceptable level of interlaboratory variability has hampered its clinical utility. The International Ki67 in Breast Cancer Working Group has undertaken a systematic programme to determine whether Ki67 measurement can be analytically validated and standardised among laboratories. This study addresses whether acceptable scoring reproducibility can be achieved on excision whole sections.

[1]  David L Rimm,et al.  Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study , 2018, Laboratory Investigation.

[2]  John M S Bartlett,et al.  An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer , 2018, Modern Pathology.

[3]  M. Rantalainen,et al.  Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer , 2018, Histopathology.

[4]  M. Ellis,et al.  Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer , 2018, Current Treatment Options in Oncology.

[5]  Ning Wang,et al.  Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review , 2018, BMJ Open.

[6]  M. Dowsett,et al.  Abstract GS1-03: Peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer – The POETIC* Trial (CRUK/07/015) , 2018 .

[7]  Bert van der Vegt,et al.  Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement , 2018, Breast Cancer Research and Treatment.

[8]  E. Enwere,et al.  The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer , 2018, PloS one.

[9]  E. Balslev,et al.  An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG) , 2018, Acta oncologica.

[10]  Y. Nordby,et al.  Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort , 2017, PloS one.

[11]  Eberhard Korsching,et al.  Interlaboratory variability of Ki67 staining in breast cancer. , 2017, European Journal of Cancer.

[12]  Hong-zhao Li,et al.  Prognostic and clinicopathological role of high Ki-67 expression in patients with renal cell carcinoma: a systematic review and meta-analysis , 2017, Scientific Reports.

[13]  T. Katagiri,et al.  Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers , 2017, Oncotarget.

[14]  L. Neumayer,et al.  POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase Compliance) trial: Changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen. , 2017, Breast.

[15]  J. Olson,et al.  Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  John M S Bartlett,et al.  Abstract P1-01-01: Analytical validation of a standardized scoring protocol for Ki67: Phase-3 of an international multicenter collaboration , 2016 .

[17]  Minfeng Chen,et al.  The Prognostic Role of Ki-67/MIB-1 in Upper Urinary-Tract Urothelial Carcinomas: A Systematic Review and Meta-Analysis. , 2015, Journal of endourology.

[18]  Carsten Denkert,et al.  Strategies for developing Ki67 as a useful biomarker in breast cancer. , 2015, Breast.

[19]  M. Desouki,et al.  The role of immunohistochemistry in the evaluation of gynecologic pathology part 2: a comparative study between two academic institutes. , 2015, Annals of diagnostic pathology.

[20]  S. Barni,et al.  Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients , 2015, Breast Cancer Research and Treatment.

[21]  M. Fernö,et al.  Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines – a Swedish survey with central re-assessment , 2015, Acta oncologica.

[22]  John M S Bartlett,et al.  An international study to increase concordance in Ki67 scoring , 2015, Modern Pathology.

[23]  A. Goldhirsch,et al.  High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. , 2014, Breast.

[24]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[25]  John M S Bartlett,et al.  An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.

[26]  F. Zeman,et al.  Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry , 2013, Breast Cancer Research and Treatment.

[27]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[28]  Pierre-Marie Martin,et al.  Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review , 2011, Breast Cancer Research and Treatment.

[29]  M. Dowsett,et al.  Comparative validation of the SP6 antibody to Ki67 in breast cancer , 2010, Journal of Clinical Pathology.

[30]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[31]  R. Gelber,et al.  Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. , 2008, Journal of the National Cancer Institute.

[32]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  C. Sotiriou,et al.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients , 2007, British Journal of Cancer.

[34]  Mitch Dowsett,et al.  Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.

[35]  T. Kirkegaard,et al.  Observer variation in immunohistochemical analysis of protein expression, time for a change? , 2006, Histopathology.

[36]  Thomas Rüdiger,et al.  Inter‐laboratory and inter‐observer reproducibility of immunohistochemical assessment of the Ki‐67 labelling index in a large multi‐centre trial , 2002, The Journal of pathology.

[37]  Johannes Gerdes,et al.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.